Market Overview

Cell Therapeutics Patient Access Scheme Approved by NICE in UK

Cell Therapeutics (NASDAQ: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, has notified CTI and issued a statement on their website stating that CTI's patient access scheme has been approved by the Department of Health and the appeal stage of this appraisal topic is suspended.  The draft final appraisal document (FAD) and evaluation report have been removed from the NICE website, since it is no longer relevant.  

NICE has agreed that the Appraisal Committee will consider the new evidence on the cost effectiveness of PIXUVRI at its meeting on 11 September 2013.

"We are very pleased to receive this positive notice and look forward to collaborating with NICE during the final stage of the process in order to bring this new approved therapy to patients in the UK with aggressive non-Hodgkin lymphoma in the 3rd line salvage setting," said James A. Bianco, M.D., President and CEO of CTI.

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (CTIC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free